NCI Solicits Views on Cancer Study Invention Rights
Published Date: 6/27/2025
Notice
Summary
The National Cancer Institute’s Division of Cancer Prevention wants your thoughts on a new rule about who owns inventions made during certain cancer studies. This rule would affect groups working with NCI-funded projects that use special tech or drugs from NCI collaborators. If approved, it could change how intellectual property is shared in current and future studies, so get ready to weigh in soon!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
New NCI 'IP Option' for Collaborators
If you run or work for an entity that conducts Division of Cancer Prevention (DCP)‑funded clinical studies and your project uses a proprietary agent or technology provided by an NCI collaborator, a proposed standard policy called the “IP Option” could apply to you. The policy would be added as a term to applicable existing and future DCP funding agreements and could change how intellectual property developed by funding recipients is handled. The National Cancer Institute is asking for public comments on this proposed policy.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06501 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a cool new invention—special human antibodies that can fight certain cancers and autoimmune diseases—for companies to license and develop into treatments. This means businesses can jump on this opportunity to create powerful new medicines using government-backed research. Interested parties should act soon and may need to sign agreements to get full details.
2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration
The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!
2026-05957 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.
2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings
The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.
2026-05673 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)
The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!
Previous / Next Documents
Previous: 2025-11857 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Survey of Construction: Questionnaire for Building Permit Official
The Department of Commerce wants to keep asking building permit officials some important questions about construction through a survey. They’re asking for your thoughts for 60 days before sending the survey for final approval. This helps make sure the survey isn’t too much work and keeps construction data accurate and up-to-date.
Next: 2025-11860 — Guidance on Referrals for Potential Criminal Enforcement
The Department of Commerce is rolling out new rules to spot and report serious rule-breaking that could lead to criminal charges. This affects businesses and people who follow federal rules, making sure only the really bad stuff gets punished. Starting May 9, 2025, expect sharper focus on criminal enforcement, helping save time and money by cutting down on unnecessary penalties.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in